NCT01621412

Brief Summary

The investigators believe that disclosure of HIV status could influence medication adherence. If disclosure leads to social support, adherence could be improved. This study purpose is to assess correlation between disclosure and medication adherence, and to describe people whose HIV status has been disclosed to.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 31, 2012

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 18, 2012

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

December 22, 2015

Status Verified

December 1, 2015

Enrollment Period

1.2 years

First QC Date

May 31, 2012

Last Update Submit

December 21, 2015

Conditions

HIV Infection

Keywords

Medication AdherenceHIV infectionDisclosure

Outcome Measures

Primary Outcomes (1)

  • Patient Adherence

    Electronic monitoring of adherence during 30 days before survey

    30 days before survey

Secondary Outcomes (1)

  • Patient Adherence

    90 days before survey

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients enrolled in the adherence-enhancing program at ther pharmacy of Department of Ambulatory Care and Community Medicine in Lausanne

You may qualify if:

  • HIV Infection
  • Enrolled in the adherence-enhancing program

You may not qualify if:

  • Not french or english speaker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Policlinique Médicale Universitaire

Lausanne, Canton of Vaud, 1011, Switzerland

Location

MeSH Terms

Conditions

HIV InfectionsMedication Adherence

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

  • Marie-Paule Schneider, PhD

    Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

    PRINCIPAL INVESTIGATOR

  • Aurélie Gertsch, PhD-Student

    Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

    PRINCIPAL INVESTIGATOR

  • Olivier Bugnon, Professor

    Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

    STUDY CHAIR

  • Matthias Cavassini, MD

    Centre Hospitalier Universitaire Vaudois

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Pharmacist, PhD

Study Record Dates

First Submitted

May 31, 2012

First Posted

June 18, 2012

Study Start

April 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

December 22, 2015

Record last verified: 2015-12

Locations

CH(1)